Abstract Patients (pts) with polycythemia vera (PV) suffer from pruritus, night sweats, and other symptoms, as well as from thromboembolic complications and progression to post-PV myelofibrosis. Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistance. The RuxoBEAT trial (NCT02577926, registered on October 1, 2015, at clinicaltrials.gov) is a […]
Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & Disease. The JAK1/2 inhibitor ruxolitinib demonstrates clinical activity among patients with MPN (eg, essential thrombocythemia, primary myelofibrosis, polycythemia vera), but rarely produces a complete response. Data from previous studies […]
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients with polycythemia […]
A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining to the care of patients with chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) in this Best of the Day discussion from the annual hematology meeting […]
THE STORY OF JAK2 Four teams race to find the mysterious cause of a group of blood cancers. JAK2 MUTATIONS AT A GLANCE Involved in: blood cancers and disorders including polycythemia vera, primary myelofibrosis, thrombocythemia, leukemia. Testing requires: a blood draw. Bone marrow samples occasionally used. Prognosis: Patients with a JAK2 mutation have a lower […]
Site by: Kaleidoscopic
